Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Multidisciplinary therapy comparable to standard treatment for cutting cardiovascular markers in ACS

06 Dec 2019

Screening for obstructive sleep apnoea and multifaceted treatment during the subacute phase of acute coronary syndrome (ACS) does not lower cardiovascular marker levels more than standard therapy, a recent study has found.

Researchers randomly assigned 159 patients to receive either sleep-study guided multidisciplinary therapy (SGMT; n=70; mean age, 55.6±9.0 years; 91.4 percent male) or standard therapy (n=89; mean age, 54.2±7.4 years; 87.6 percent male). The primary study endpoint was the change in plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) levels after 7 months.

NT-proBNP decreased with time in both treatment arms. No significant between-group differences were reported at baseline (579±1,117 vs 611±899 pg/dL; p=0.851) and after 4 (115±222 vs 114±226 pg/dL; p=0.990) and 7 (90±167 vs 93±174 pg/dL; p=0.996) months of follow-up.

Similarly, the magnitudes of change from baseline were comparable between groups after 4 (–464 vs –497 pg/dL; p=0.792) and 7 (–489 vs –518 pg/dL; p=0.726) months.

Levels of plasma suppression of tumorigenicity 2 and high-sensitivity C-reactive protein likewise were not significantly different between the two groups.

These resulted in similar risks. At the 7-month follow-up, the estimated likelihood of developing fatal cardiovascular disease within 10 years was 2.1±1.8 percent in the SGMT group and 2.0±2.4 percent in the controls (p=0.176). At this time point, major adverse cardiac and cerebrovascular events also occurred with comparable frequencies between groups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.